China SXT Pharmaceuticals annual net income
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
China SXT Pharmaceuticals Net Income Growth & History (SXTC)
China SXT Pharmaceuticals's net income was −$6.2M for fiscal 2026.
View full China SXT Pharmaceuticals company overviewChina SXT Pharmaceuticals annual net income history
| Fiscal year | Period ended | Net income | Change | Growth |
|---|---|---|---|---|
| 2026 | 2026-03-31 | −$6.2M | −$2.9M | — |
| 2025 | 2025-03-31 | −$3.3M | −$205,120 | — |
| 2024 | 2024-03-31 | −$3.1M | $2.8M | — |
| 2023 | 2023-03-31 | −$5.9M | −$198,677 | — |
| 2022 | 2022-03-31 | −$5.7M | −$3.0M | — |
| 2021 | 2021-03-31 | −$2.7M | $7.5M | — |
| 2020 | 2020-03-31 | −$10.3M | −$11.8M | — |
| 2019 | 2019-03-31 | $1.5M | $351,646 | +29.61% |
| 2018 | 2018-03-31 | $1.2M | $2,435 | +0.21% |
| 2017 | 2017-03-31 | $1.2M | — | — |
China SXT Pharmaceuticals net income trends
Over the last five fiscal years, China SXT Pharmaceuticals's net income decreased from −$2.7M to −$6.2M, a change of −$3.5M.
About the metric
What net income means
Net income is a company’s bottom-line profit or loss after operating costs, interest, taxes, and other reported income and expenses. It shows how much of a company’s revenue ultimately remained as earnings, or how large its loss was, during a fiscal period.
Calculation and source
SEC-reported net income
TickerStat standardizes consolidated net income or profit and loss reported in company SEC filings for aligned fiscal periods. It is not adjusted earnings, an analyst estimate, or company guidance. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review China SXT Pharmaceuticals source filings ↗